News

Rituximab is a monoclonal antibody that is used to treat non-Hodgkin’s lymphoma, which includes follicular lymphoma and diffuse large B-cell lymphoma, chronic lymphocytic leukemia and autoimmune diseases such

A new research team of scientists established by the companies had submitted the most promising solution approaches in a crowdsourcing competition. The interdisciplinary team, which will be led

Darzalex, which is being developed jointly by Genmab and Janssen Biotech, is a human IgG1k monoclonal antibody that binds to CD38, a protein expressed on the surface of

The objective of SPARTAN is to evaluate the safety and efficacy of lasmiditan (50 mg, 100 mg and 200 mg) in comparison to placebo two hours after dosing

Patients will be at least 18 years of age with a maximum of 10% treatable body surface area (BSA) involvement of plaque psoriasis. Up to 15 patients will

Anavex Life Sciences president and CEO Christopher U. Missling said: "The Orphan Drug Designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease

PDI Therapeutics will focus on the development of novel stand-alone or combination immunotherapies to enlist the body’s immune system for fighting cancer. The company is named for protein

Plumiaz failed to demonstrate its bioequivalence to Diastat rectal gel, which was required to support a refiling of the nasal spray’s new drug application earlier planned for the

Pfizer’s application was based a clinical trial dataset of about 20,800 adolescents, as well as adults aged 10 years and older, studied across the globe. The company noted